DOCSLIB.ORG

National Institute for Clinical Excellence

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
National Institute for Clinical Excellence NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (review of TA397) [ID1591] Matrix of consultees and commentators Consultees Commentators (no right to submit or appeal) Company/sponsor General commentators • GlaxoSmithKline • All Wales Therapeutics and Toxicology Centre Patient/carer groups • Allied Health Professionals • Action for Sick Children Federation • Action on Pain • Board of Community Health Councils • Anticoagulation UK in Wales • Arthritis Action • British National Formulary • Arthritis & Musculoskeletal Alliance • Care Quality Commission • Black Health Agency • Cell and Gene Therapy Catapult • British Sjögren’s Syndrome • Department of Health, Social Services Association and Public Safety for Northern Ireland • Changing Faces • Healthcare Improvement Scotland • Contact • Hospital Information Services - • Disability Rights UK Jehovah's Witnesses • Genetic Alliance UK • Medicines and Healthcare Products • Jnetics Regulatory Agency • Kidney Care UK • National Association of Primary Care • Leonard Cheshire Disability • National Pharmacy Association • Let’s Face It • NHS Alliance • Lupus Trust • NHS Confederation • Lupus UK • NHS England Specialised • National Children's Bureau Rheumatology Clinical Reference • National Kidney Federation Group • National Rheumatoid Arthritis Society • Scottish Medicines Consortium • Pain Concern • Welsh Health Specialised Services • Pain Relief Foundation Committee • Pain UK • Welsh Kidney Patients Association • Psoriasis and Psoriatic Arthritis Alliance Comparators • Psoriasis Association • Baxter Healthcare (cyclophosphamide) • Celltrion (rituximab biosimilar) • Psoriasis Help Organisation • Pfizer (cyclophosphamide) • South Asian Health Foundation • Roche Pharmaceuticals (rituximab) • Specialised Healthcare Alliance • Sandoz GmbH (rituximab biosimilar) • Thrombosis UK • Versus Arthritis Relevant research groups • Bone Research Society Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (review of TA397) [ID1591] Issue date: August 2020 © National Institute for Health and Care Excellence 2020. All rights reserved. Page 1 of 4 Professional groups • British Epidermo-Epidemiology Society • Association of Genetic Nurses & • British Society for Immunology Counsellors • Centre of Evidence-Based • Association of Renal Industries Dermatology, University of Nottingham • Association of Renal Technologists • Chronic Pain Policy Coalition • British Association for Surgery of the • Cochrane Cystic Fibrosis & Genetic Knee Disorders Group • British Association of Dermatologists • Cochrane Musculoskeletal Group • British Dermatological Nursing Group • Cochrane Skin Group • British Geriatrics Society • Cochrane Vascular • British Institute of Musculoskeletal • Genomics England Medicine • Kidney Research UK • British Myology Society • MRC Clinical Trials Unit • British Isles Lupus Assessment Group • National Institute for Health Research • British Orthopaedic Association • Orthopaedic Research UK • British Orthopaedic Foot and Ankle • Skin Treatment and Research Trust Society • Thrombosis Research Institute • British Pain Society • British Renal Society Associated Guideline Groups • British Skin Foundation • National Guidelines Centre • British Society for Allergy and Clinical Immunology Associated Public Health Groups • British Society for Children's • Public Health England Orthopaedic Surgery • Public Health Wales • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Society for Human Genetics • British Society for Rheumatology • British Society for Paediatric and Adolescent Rheumatology • British Society of Rehabilitation Medicine • British Thoracic Society • • Clinical Leaders of Thrombosis • Physiotherapy Pain Association • Primary Care Dermatology Society • Primary Care Rheumatology & Musculoskeletal Society • Renal Association • Rheumatoid Arthritis Surgical Society • Royal College of General Practitioners • Royal College of Nursing Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (review of TA397) [ID1591] Issue date: August 2020 © National Institute for Health and Care Excellence 2020. All rights reserved. Page 2 of 4 • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • Society for Vascular Technology of Great Britain and Ireland • Society of Vascular Nurses • The Vascular Society of Great Britain and Ireland • UK Clinical Pharmacy Association • UK Genetic Testing Network • United Kingdom Primary Immunodeficiency Network • UK Renal Pharmacy Group Others • Department of Health and Social Care • NHS Bexley CCG • NHS England • NHS West London CCG • Welsh Government NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues. PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (review of TA397) [ID1591] Issue date: August 2020 © National Institute for Health and Care Excellence 2020. All rights reserved. Page 3 of 4 MTA Definitions: Consultees Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England. The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD). All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD). Commentators Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary. All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee. Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (review of TA397) [ID1591] Issue date: August 2020 © National Institute for Health and Care Excellence 2020. All rights reserved. Page 4 of 4 .
Load more

Recommended publications
  • Thrombosis Uk for the Year Ended 31 Janiiary 2016
    THROMBOSIS UK (Formerly known as Lifeblood: The Thrombosis Charity) (A Company Limited by Guarantee) REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANIIARY 2016 Registered Charity No: 1090540 Company No: 4354472 THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 TRUSTEES AND MANAGEMENT Trustees Shelley Anne Webster, LLB, PgDL, BVC- (Chair until 01.06.16) Dr Beverley Jane Hunt, MD, FRCP, FRCPath Simon Hart, FCCA. Kim Lesley Carter Dr Simon Noble Professor lan Maxwell Franklin (Chair from 01.06.16) Robin Offord Paul Westerman Clare Mary Reynolds Andrea Louise Croft Raanan Evelyn ZVI Gillon (Resigned on 25.06.16) Dr Matthew Robert Fay (Appointed on 20.02.15) Secretary Dr B J Hunt, MD, FRCP, FRCPath Council of Reference Professor Lesley Regan MD, FRCOG Professor E G D Tuddenham, MBBS, FRCP, FRCPath, FRCPE, MD Dr A T Cohen MBBS, MSc, MD, FRACP Registered office 91 Gower Street London WC1E 6AB Auditors Couch Bright King & Co Chartered Accountants 91 Gower Street London WC1E 6AB Solicitors Stone King 28 Ely Place London ECIN 6TD Bankers National Westminster Bank pic Maids Vale Elgin Avenue Branch 298 tlgin Avcnuc London W91WT THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2016 The Trustees present their report along with the financial statements of the charity for the year ended 31 January 2016. The financial statements have been prepared in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015) and follow the recommendations in Accounting and Reporting by Charities: Statement of Recommended Practice (SORP 2015).
    [Show full text]
  • RCN International Centenary Conference Book of Abstracts
    RCN International Centenary Conference Book of abstracts 22 and 23 November 2016 QEII Centre, London SW1P 3EE Sponsored by 2 Contents Main hall chair biographies 4 Wednesday 23 November 2016 66 Keynote lectures 66 Tuesday 22 November 2016 6 Keynote lectures 6 Wednesday 23 November 2016 68 Concurrent session 3 68 Theme: Society, communities, relationships 68 Tuesday 22 November 2016 8 Theme: Society, communities, relationships 70 Concurrent session 1 8 Theme: Society, communities, relationships 71 Theme: Society, communities, relationships 8 Theme: Technology and innovation 73 Theme: Society, communities, relationships 11 Theme: Knowledge for change and improvement 75 Theme: Technology and innovation 14 Theme: Knowledge for change and improvement 75 Theme: Technology and innovation 17 Theme: Knowledge for change and improvement 77 Theme: Conflicts, disaster and recovery 20 Theme: Knowledge for change and improvement 78 Theme: Conflicts, disaster and recovery 22 Theme: Knowledge for change and improvement 80 Theme: Populations, health and economic growth 25 Theme: Knowledge for change and improvement 82 Theme: Populations, health and economic growth 28 Theme: Knowledge for change and improvement 34 Theme: Knowledge for change and improvement 37 Wednesday 23 November 2016 84 Concurrent session 4 84 Theme: Societies, communities, relationships 84 Tuesday 22 November 2016 40 Theme: Societies, communities, relationships 87 Concurrent session 2 40 Theme: Society, communities, relationships 89 Theme: Society, communities, relationships 40 Theme:
    [Show full text]
  • Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID- 19
    Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Journal Pre-proof COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up Behnood Bikdeli, MD, MS, Mahesh V. Madhavan, MD, David Jimenez, MD, PhD, Taylor Chuich, PharmD, Isaac Dreyfus, MD, Elissa Driggin, MD, Caroline Der Nigoghossian, PharmD, Walter Ageno, MD, Mohammad Madjid, MD, MS, Yutao Guo, MD, PhD, Liang V. Tang, MD, Yu Hu, MD, Jay Giri, MD, MPH, Mary Cushman, MD, MSc, Isabelle Quéré, MD, PhD, Evangelos P. Dimakakos, MD, C. Michael Gibson, MD, Giuseppe Lippi, MD, Emmanuel J. Favaloro, PhD, Jawed Fareed, PhD, Joseph A. Caprini, MD, MS, Alfonso J. Tafur, MD, MS, John R. Burton, BS, Dominic P. Francese, MPH, Elizabeth Y. Wang, MD, Anna Falanga, MD, Claire McLintock, MD, Beverley J. Hunt, MD, Alex C. Spyropoulos, MD, Geoffrey D. Barnes, MD, MSc, John W. Eikelboom, MBBS, Ido Weinberg, MD, Sam Schulman, MD, PhD, Marc Carrier, MD, MSc, Gregory Piazza, MD, MS, Joshua A.
    [Show full text]
  • A Feasibility Study to Inform the Design of a Randomised Controlled Trial to Identify the Most Clinically Effective and Cost-Eff
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 19 ISSUE 83 OCTOBER 2015 ISSN 1366-5278 A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT) Simon I Noble, Annmarie Nelson, David Fitzmaurice, Marie-Jet Bekkers, Jessica Baillie, Stephanie Sivell, Joanna Canham, Joanna D Smith, Angela Casbard, Ander Cohen, David Cohen, Jessica Evans, Kate Fletcher, Miriam Johnson, Anthony Maraveyas, Hayley Prout and Kerenza Hood DOI 10.3310/hta19830 A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT) Simon I Noble,1,2* Annmarie Nelson,2 David Fitzmaurice,3 Marie-Jet Bekkers,4 Jessica Baillie,5 Stephanie Sivell,2 Joanna Canham,1 Joanna D Smith,1 Angela Casbard,1 Ander Cohen,6 David Cohen,7 Jessica Evans,1 Kate Fletcher,8 Miriam Johnson,9 Anthony Maraveyas,10 Hayley Prout2 and Kerenza Hood4 1Wales Cancer Trials Unit, School of Medicine, Cardiff University, Cardiff, UK 2Marie Curie Palliative Care Research Centre, Cardiff University, Cardiff, UK 3Department of Primary Care Clinical Sciences, University of Birmingham, Edgbaston, UK 4South East Wales Trials Unit, Cardiff University, Cardiff, UK 5School of Healthcare Science, Cardiff University, Cardiff, UK 6Department of Surgery
    [Show full text]
  • Using the United Kingdom Standards for Public Involvement to Evaluate
    Seddon et al. Research Involvement and Engagement (2021) 7:22 https://doi.org/10.1186/s40900-021-00264-3 METHODOLOGY Open Access Using the United Kingdom standards for public involvement to evaluate the impact of public involvement in a multinational clinical study Kathy Seddon1, Jim Elliott2,MiriamJohnson3, Clare White4, Max Watson5, Annmarie Nelson6† and Simon Noble6*† Abstract Background: The publication of the United Kingdom (UK) Standards for Public Involvement (PI) (UK Standards) in research drew a clear line in the sand regarding the importance of utilising the unique experience, skills and expertise that lay people may offer to the development, conduct and dissemination of clinical research. The UK Standards provide a benchmark which researchers should aim to achieve, yet its implementation continues to be a step wise iterative process of change management. A recent evaluation by a regional research group has suggested that our understanding of PI is enhanced through reflection on the UK Standards. We report on the utility of PI in the design, conduct and dissemination of the HIDDen study, a national, multicentre clinical study based across three UK centres. Methods: A retrospective review of PI within the HIDDen study was conducted using field notes taken by the lead author from interactions throughout their involvement as a lay representative on the study. Key members of the HIDDen study were interviewed and data analysed to explore adherence to the UK Standards. Results: There was universal support for PI across the study management group with genuine inclusivity of lay members of the committee. All six of the UK Standards were met to varying degrees.
    [Show full text]
  • Annual Report and Financial Statements 31St
    cc THROMBOSIS UK (Formerly known as Lifeblood: The Thrombosis Charity) (A Company Limited by Guarantee) REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2018 Registered Charity No: 1090540 Company No: 4354472 L3174-18 THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2018 REFERENCE AND ADMINISTRATION DETAILS: TRUSTEES AND MANAGEMENT Trustees Shelley Anne Webster, LLB, PgDL, BVC - Professor Beverley Jane Hunt, MD, FRCP, FRCPath Simon Hart, FCCA. Professor Simon Noble Professor Ian Maxwell Franklin Robin Offord Paul Westerman (Resigned 28.06.18) Andrea Louise Croft Dr Matthew Robert Fay Mr Shaull Watson Kinghorn (Appointed 10.01.18) Mr Stephane Jaglin (Appointed 10.0l.18) CEO Ja Jerrome Secretary Professor B J Hunt, MD, FRCP, FRCPath Registered office Shropshire House 179 Tottenham Court Road London WIT7NZ Auditors Couch Bright King & Co Chartered Accountants Shropshire House 179 Tortenharn Court Road London W1T7NZ Solicitors Stone King 28 Ely Place London ECIN 6TD Bankers National Westminster Bank pIc Maida Vale Elgin Avenue Branch 298 Elgin Avenue London W91WT 2 THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2018 The Trustees present their annual report together with the financial statements of the charity for the year ended 31 January 2018. The financial statements have been prepared in accordance with the accounting policies set out on pages 13 to 14 and comply with the Charities Act 20 I I, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Memorandum and Articles of Association, Accounting and Reporting by Cbarities: Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland published on 16 July 2014 and the Companies Act 2006.
    [Show full text]
  • Across Enemy Lines: a Study of the All-Party Groups in the Parliaments of Canada, Ontario, Scotland and the United Kingdom
    Across Enemy Lines: a Study of the All-Party Groups in the Parliaments of Canada, Ontario, Scotland and the United Kingdom by Paul E.J. Thomas A thesis submitted in conformity with the requirements for the degree of Doctorate of Philosophy Department of Political Science University of Toronto © Copyright by Paul Thomas 2016 Across Enemy Lines: a Study of the All-Party Groups in the Parliaments of Canada, Ontario, Scotland and the United Kingdom Paul E.J. Thomas Doctor of Philosophy Department of Political Science University of Toronto 2016 Abstract The Parliaments of Canada, Ontario, Scotland and the United Kingdom are now home to a growing number of informal bodies that are formed by politicians from all parties who wish to cooperate on specific policy issues or relations with other countries. Such all-party groups (APGs), which deal with topics from the steel industry to genocide prevention, work to share information, meet with stakeholders, and conduct policy studies. Most also have partnerships with external actors who support their activities. This dissertation explores why the number of APGs is rising in each jurisdiction, but also why there are relatively fewer APGs in the two Canadian cases. Using statistical analyses of APG membership patterns as well as interviews with parliamentarians, lobbyists, and journalists, it finds three main factors behind APG expansion. First, the growth of APGs has helped both parliamentarians and external actors to continue to achieve their goals despite changes in the external political environment such as rising policy complexity and increased demands from citizens. Second, APG expansion has been facilitated by the evolution and increasing modularity of the APG format, which has allowed it to be adapted to a broader range of issues and activities.
    [Show full text]
  • Fourth Assembly Legacy Report
    National Assembly for Wales Health and Social Care Committee Fourth Assembly Legacy Report March 2016 The National Assembly for Wales is the democratically elected body that represents the interests of Wales and its people, makes laws for Wales and holds the Welsh Government to account. An electronic copy of this report can be found on the National Assembly’s website: www.assembly.wales Copies of this report can also be obtained in accessible formats including Braille, large print, audio or hard copy from: Health and Social Care Committee National Assembly for Wales Cardiff Bay CF99 1NA Tel: 0300 200 6565 Email: [email protected] Twitter: @SeneddHealth © National Assembly for Wales Commission Copyright 2016 The text of this document may be reproduced free of charge in any format or medium providing that it is reproduced accurately and not used in a misleading or derogatory context. The material must be acknowledged as copyright of the National Assembly for Wales Commission and the title of the document specified. National Assembly for Wales Health and Social Care Committee Fourth Assembly Legacy Report March 2016 Committee remit The Committee was established on 22 June 2011 with a remit to examine legislation and hold the Welsh Government to account by scrutinising expenditure, administration and policy matters encompassing: the physical, mental and public health of the people of Wales, including the social care system. Matters relating to the health and wellbeing of children and young people, including their social care, sat
    [Show full text]
  • Aspirin and the Prevention of Venous Thromboembolism Following Total Joint Arthroplasty COMMONLY ASKED QUESTIONS I
    SPECIALTY UPDATE: ARTHROPLASTY Aspirin and the prevention of venous thromboembolism following total joint arthroplasty COMMONLY ASKED QUESTIONS I. Azboy, The number of arthroplasties being performed increases each year. Patients undergoing an R. Barrack, arthroplasty are at risk of venous thromboembolism (VTE) and appropriate prophylaxis has A. M. Thomas, been recommended. However, the optimal protocol and the best agent to minimise VTE F. S. Haddad, under these circumstances are not known. Although many agents may be used, there is a J. Parvizi difference in their efficacy and the risk of bleeding. Thus, the selection of a particular agent relies on the balance between the desire to minimise VTE and the attempt to reduce the risk From Rothman of bleeding, with its undesirable, and occasionally fatal, consequences. Institute, Acetylsalicylic acid (aspirin) is an agent for VTE prophylaxis following arthroplasty. Many Philadelphia, United studies have shown its efficacy in minimising VTE under these circumstances. It is States inexpensive and well-tolerated, and its use does not require routine blood tests. It is also a ‘milder’ agent and unlikely to result in haematoma formation, which may increase both the risk of infection and the need for further surgery. Aspirin is also unlikely to result in persistent wound drainage, which has been shown to be associated with the use of agents such as low-molecular-weight heparin (LMWH) and other more aggressive agents. The main objective of this review was to summarise the current evidence relating to the I. Azboy, MD, Associate efficacy of aspirin as a VTE prophylaxis following arthroplasty, and to address some of the Professor of Orthopaedic common questions about its use.
    [Show full text]
  • Anticoagulation Uk Champion Support Pack
    UKXAR02170074a April 2017 ANTICOAGULATION UK CHAMPION SUPPORT PACK Prioritising clot prevention in your local area Social Care Awards 2017 AntiCoagulation Europe Best Anticoagulant Support Charity 2017 - UK Support for Anticoagulation UK with this project has been provided by MHP Health, whose services are paid for by Bayer. Bayer has checked the content of materials for factual accuracy and compliance with the ABPI code of practice. Editorial control rests with Anticoagulation UK. CONTENTS Introduction 02 Why do we need your help? 03 Anticoagulation: Top ten facts 04 Our work to improve anticoagulation services 06 Anticoagulation in a local setting 07 How to get in touch with different stakeholders: – Contact your MP 11 – Contact your local councillor(s) 13 – Contact your local Clinical Commissioning Group 14 – Contact your local Health Watch 15 – Contact your local media 16 How might you use this support pack? 18 More information about anticoagulation 20 Glossary 22 Useful links 23 Template resources 24 UKXAR02170074a April 2017 1 INTRODUCTION Welcome to our Anticoagulation UK Champion programme, we hope you are going to enjoy the experience. In 2000, after two years of market research and identifying the lack of information around anticoagulation therapy, Anticoagulation UK was launched as a charitable organisation to provide information, education and support to individuals who required anticoagulation therapy in the short term or as a life-long treatment for their specific condition. 17 years of proactivity has produced some significant achievements in terms of patient outcomes and these include access to NHS prescriptions for self-monitoring strips for warfarin patients, VTE risk assessment protocols for hospital inpatients to minimise risk of hospital acquired thrombosis, campaigning for anticoagulants to be given to patients diagnosed with atrial fibrillation to reduce stroke risk and most recently, raising awareness of cancer associated thrombosis (CAT) for patients undertaking chemotherapy.
    [Show full text]
  • Stakeholder List PDF 126 KB
    Atrial fibrillation: management Stakeholders Abbott Laboratories Abbott Medical Action Heart Action on Smoking and Health AF Association Affinity Care AliveCor Ltd All Party Parliamentary Group on Vascular and Venous Disease Allergan Aneurin Bevan University Health Board Anticoagulation UK Aortic Dissection Awareness UK and Ireland AQuA Arrhythmia Alliance Association of Anaesthetists of Great Britain and Ireland Association of British HealthTech Industries Association of Naturopathic Practitioners Atrial Fibrillation Association AtriCure, Inc. Bayer plc Betsi Cadwaladr University Health Board Birmingham City University blackpool teaching hospitals nhs trust Blood Pressure UK Boehringer Ingelheim Boston Scientific Bourne Hall Health Centre Brighton and Sussex University Hospital NHS Trust Bristol-Myers Squibb Pharmaceuticals Ltd British & Irish Hypertension Society British Acupuncture Council British and Irish Society for Minimally Invasive Cardiac Surgery British Association for Cardiovascular Prevention & Rehabilitation British Association of Cardiologists of Indian Origin British Association of Stroke Physicians British Cardiovascular Society British Dietetic Association British Geriatrics Society British Heart Rhythm Society British Medical Association British Medical Journal British Nuclear Cardiology Society British Psychological Society British Society for Haematology British Society for Haematology British Society for Heart Failure Cardiovascular Care Partnership Care Quality Commission Castle Hill Hospital Centre for Pharmacy
    [Show full text]
  • Venous Thromboembolism in Over 16S: Reducing the Risk of Hospital-Acquired Deep Vein Thrombosis Or Pulmonary Embolism (Update) Stakeholders
    Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (Update) Stakeholders Academy for Healthcare Science Active Lifestyles, Salford Community Leisure Alere Ltd AntiCoagulation Europe ArjoHuntleigh Ashford and St Peter's Hospitals NHS Trust Association for Perioperative Practice Association of Anaesthetists of Great Britain and Ireland Association of Directors of Public Health Association of Independent Healthcare Organisations Astrazeneca UK Ltd Atrial Fibrillation Association Australian Commission on Safety and Quality in Health Care Barnet Enfield and Haringey Mental Health Trust Barnsley Hospital NHS Foundation Trust Barts Health NHS Trust Basildon and Thurrock University Hospitals NHS Foundation Trust Bayer plc Belfast Health and Social Care Trust Besins Healthcare Betsi Cadwaladr University Health Board BHR Pharmaceuticals Ltd Biocompatibles Birmingham Women’s NHS Foundation Trust Black and Ethnic Minority Diabetes Association Boehringer Ingelheim Ltd Bolton Council Boston Scientific Bristol-Myers Squibb Pharmaceuticals Ltd British Association of Critical Care Nurses British Association of Day Surgery British Association of Prosthetists & Orthotists British Dietetic Association British Geriatrics Society British Heart Foundation British Lymphology Society British Medical Association British Medical Journal British National Formulary British Nuclear Cardiology Society British Orthopaedic Association British Pregnancy Advisory Service British Psychological Society British
    [Show full text]